Wedbush Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price

Key Points

• Wedbush raised its price objective to $105 and keeps an "outperform" rating, implying about a 16.36% upside$117.82.
• Shares opened at $90.24 (1-year range $16.64–$96.50) with a market cap of $4.91B; Dianthus beat quarterly EPS estimates (-$0.85 vs. -$1.10) but still reports deeply negative margins and a negative P/E (-22.01).
• Significant insider selling has occurred—323,021 shares (~$26.56M) sold in the last three months (insiders now own 3.02%)—while institutional investors hold about 47.5% of the stock.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) had its price objective upped by research analysts at Wedbush from $103.00 to $105.00 in a report released on Wednesday,Benzinga reports. The firm presently has an "outperform" rating on the stock. Wedbush's target price would indicate a potential upside of 16.36% from the stock's current price.

DNTH has been the subject of a number of other reports. William Blair reaffirmed an "outperform" rating on shares of Dianthus Therapeutics in a report on Monday, March 16th. Robert W. Baird increased their price objective on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the company an "outperform" rating in a report on Tuesday, March 10th. Oppenheimer increased their target price on Dianthus Therapeutics to $145.00 and gave the company an "outperform" rating in a research report on Monday, March 9th. Truist Financial increased their target price on Dianthus Therapeutics from $63.00 to $110.00 and gave the company a "buy" rating in a research report on Monday, March 9th. Finally, Wolfe Research started coverage on Dianthus Therapeutics in a research report on Thursday, April 9th. They set an "outperform" rating and a $98.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $117.82.

Dianthus Therapeutics Price Performance

Shares of DNTH opened at $90.24 on Wednesday. Dianthus Therapeutics has a 1 year low of $16.64 and a 1 year high of $96.50. The company has a 50 day simple moving average of $79.60 and a two-hundred day simple moving average of $55.57. The firm has a market cap of $4.91 billion, a P/E ratio of -22.01 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.10) by $0.25. Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. The business had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.40 million. On average, sell-side analysts anticipate that Dianthus Therapeutics will post -4.46 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Ryan Savitz sold 8,224 shares of the firm's stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $89.84, for a total value of $738,844.16. Following the completion of the sale, the executive vice president directly owned 8,224 shares in the company, valued at $738,844.16. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Edward Carr sold 43,682 shares of the firm's stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $3,559,646.18. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 323,021 shares of company stock valued at $26,564,008 in the last three months. Corporate insiders own 3.02% of the company's stock.

Institutional Trading of Dianthus Therapeutics

Institutional investors have recently bought and sold shares of the stock. Patient Square Capital LP bought a new stake in Dianthus Therapeutics in the third quarter worth $4,919,000. Vanguard Group Inc. lifted its position in Dianthus Therapeutics by 13.6% in the third quarter. Vanguard Group Inc. now owns 1,642,198 shares of the company's stock worth $64,620,000 after buying an additional 196,117 shares during the last quarter. Fairmount Funds Management LLC lifted its position in Dianthus Therapeutics by 22.2% in the third quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company's stock worth $130,138,000 after buying an additional 600,000 shares during the last quarter. Braidwell LP bought a new stake in Dianthus Therapeutics in the third quarter worth $32,859,000. Finally, SG Americas Securities LLC bought a new stake in shares of Dianthus Therapeutics during the fourth quarter worth $765,000. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.